featured
Resolution of Secondary Hemophagocytic Lymphohistiocytosis After Treatment With the JAK1/2 Inhibitor Ruxolitinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Resolution of Secondary Hemophagocytic Lymphohistiocytosis After Treatment With the JAK1/2 Inhibitor Ruxolitinib
Blood Adv 2019 Dec 10;3(23)4131-4135, SR Goldsmith, S Saif Ur Rehman, CL Shirai, K Vij, JF DiPersioFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.